Use of a combination of prednisolone and rosuvastatin for treatment of a pyogranuloma in a dog

Journal of the American Veterinary Medical Association

Volumn 236, Issue 7, 2010, Pages 767-769

  Yuki, Masashi ^a   Hirano, Takashi ^a  

^a Yuki Animal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 77950942649     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.236.7.767     Document Type: Article

References (25)

1. Yamagishi C, Momoi Y, Kobayashi T, et al. A retrospective study and gene analysis of canine sterile panniculitis. J Vet Med Sci 2007; 69: 915-924. (Pubitemid 350132513)
2. Williams GT, Williams WJ. Granulomatous inflammation. J Clin Pathol 1983; 36: 726-733.
3. Chensue SW, Warmington K, Rudi J, et al. Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Pathol 1994; 145: 1105-1113. (Pubitemid 24345658)
4. Co DO, Hogan LH, Il-Kim S, et al. T cell contributions to the different phases of granuloma formation. Immunol Lett 2004; 92: 135-142. (Pubitemid 38470060)
5. Endo A, Tsujita Y, Kuroda M, et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977; 77: 31-36. (Pubitemid 8122952)
6. Nissen SE, Tuzcu EM, Schoenhagen P. Effea of interisiveœmpared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080. (Pubitemid 38541684)
7. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405. (Pubitemid 32730786)
8. Albert MA, Danielson E, Rifei N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammauon/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70. (Pubitemid 32606333)
9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38. (Pubitemid 40075678)
10. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949. (Pubitemid 129515901)
11. Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int 1995; 52: S112-S115.
12. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
13. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402. (Pubitemid 32001026)
14. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692. (Pubitemid 32588024)
15. McCarey DW, Mclnnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-2021. (Pubitemid 38781100)
16. Vollmer T, Key L, Durkalski T, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608. (Pubitemid 38625664)
17. Zacà V, Rastogi S, Imai M, et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007; 50: 551-557. (Pubitemid 47126770)
18. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540. (Pubitemid 34441756)
19. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.
20. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. AmJ Cardiol 2006; 97: 77C-81C.
21. Dostal LA, Juneau P, Rothwell CE. Repeated analysis of semen parameters in beagle dogs during a 2-year study with the HMG-CoA reductase inhibitor, atorvastatin. Toxicol Sci 2001; 61: 128-134. (Pubitemid 32409696)
22. Kovanen PT, Bilheimer DW, Goldstein JL, et al. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A 1981; 78: 1194-1198.
23. Tsujita Y, Kuroda M, Tanzawa K, et al. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Atherosclerosis 1979; 32: 307-313. (Pubitemid 9129788)
24. Walsh KM, Rothwell CE. Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Toxicol Pathol 1999; 27: 395-401.
25. Satoh K, Takaguri A, Itagaki M, et al. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. J Pharmacol Sci 2008; 106: 593-599. (Pubitemid 351556238)